These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 34287991)

  • 1. Handgrip strength stratifies the risk of covert and overt hepatic encephalopathy in patients with cirrhosis.
    Miwa T; Hanai T; Nishimura K; Maeda T; Ogiso Y; Imai K; Suetsugu A; Takai K; Shiraki M; Shimizu M
    JPEN J Parenter Enteral Nutr; 2022 May; 46(4):858-866. PubMed ID: 34287991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vitamin D deficiency stratifies the risk of covert and overt hepatic encephalopathy in patients with cirrhosis: A retrospective cohort study.
    Miwa T; Hanai T; Hirata S; Nishimura K; Sahashi Y; Unome S; Imai K; Shirakami Y; Suetsugu A; Takai K; Shimizu M
    Clin Nutr ESPEN; 2024 Oct; 63():267-273. PubMed ID: 38972037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A simple covert hepatic encephalopathy screening model based on blood biochemical parameters in patients with cirrhosis.
    Miwa T; Hanai T; Nishimura K; Maeda T; Tajirika S; Imai K; Suetsugu A; Takai K; Yamamoto M; Shimizu M
    PLoS One; 2022; 17(11):e0277829. PubMed ID: 36449492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A shortened Stroop test to identify covert hepatic encephalopathy and predict overt hepatic encephalopathy in patients with cirrhosis.
    Hanai T; Nishimura K; Miwa T; Maeda T; Nakahata Y; Imai K; Suetsugu A; Takai K; Shimizu M
    J Gastroenterol; 2022 Dec; 57(12):981-989. PubMed ID: 36173512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Covert hepatic encephalopathy is associated with aggressive disease progression and poor survival in patients with cirrhosis.
    Wang J; Deng MJ; Shi PM; Peng Y; Wang XH; Tan W; Wang PQ; Chen YX; Yuan ZL; Ning BF; Xie WF; Yin C
    J Dig Dis; 2023 Dec; 24(12):681-690. PubMed ID: 38108656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Covert hepatic encephalopathy is independently associated with poor survival and increased risk of hospitalization.
    Patidar KR; Thacker LR; Wade JB; Sterling RK; Sanyal AJ; Siddiqui MS; Matherly SC; Stravitz RT; Puri P; Luketic VA; Fuchs M; White MB; Noble NA; Unser AB; Gilles H; Heuman DM; Bajaj JS
    Am J Gastroenterol; 2014 Nov; 109(11):1757-63. PubMed ID: 25178701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and validation of the AMMON-OHE model to predict risk of overt hepatic encephalopathy occurrence in outpatients with cirrhosis.
    Ballester MP; Tranah TH; Balcar L; Fiorillo A; Ampuero J; Kerbert AJC; Thomsen KL; Escudero MD; Mandorfer M; Reiberger T; Shawcross DL; Romero-Gómez M; Montoliu C; Carbonell-Asins JA; Jalan R
    J Hepatol; 2023 Oct; 79(4):967-976. PubMed ID: 37277075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Animal naming test is a simple and valid tool for detecting covert hepatic encephalopathy and predicting outcomes in Chinese-speaking regions: a preliminary study.
    Huang CH; Yu TY; Tseng WJ; Huang YT; Chang SH; Hsieh SY; Chien RN; Amodio P
    Ann Med; 2023 Dec; 55(1):2236013. PubMed ID: 37494454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zinc deficiency predicts overt hepatic encephalopathy and mortality in liver cirrhosis patients with minimal hepatic encephalopathy.
    Miwa T; Hanai T; Toshihide M; Ogiso Y; Imai K; Suetsugu A; Takai K; Shiraki M; Katsumura N; Shimizu M
    Hepatol Res; 2021 Jun; 51(6):662-673. PubMed ID: 33242359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of non-selective ß-blockers on hepatic encephalopathy in patients with liver cirrhosis.
    Labenz C; Nagel M; Toenges G; Kuchen R; Schattenberg JM; Hilscher M; Huber Y; Marquardt JU; Labenz J; Galle PR; Wörns MA
    Eur J Intern Med; 2020 Dec; 82():83-89. PubMed ID: 32873457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Covert hepatic encephalopathy and spontaneous portosystemic shunts increase the risk of developing overt hepatic encephalopathy.
    Greinert R; Zipprich A; Simón-Talero M; Stangl F; Ludwig C; Wienke A; Praktiknjo M; Höhne K; Trebicka J; Genescà J; Ripoll C
    Liver Int; 2020 Dec; 40(12):3093-3102. PubMed ID: 32890428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated serum levels of glial fibrillary acidic protein are associated with covert hepatic encephalopathy in patients with cirrhosis.
    Gairing SJ; Danneberg S; Kaps L; Nagel M; Schleicher EM; Quack C; Engel S; Bittner S; Galle PR; Schattenberg JM; Wörns MA; Luessi F; Marquardt JU; Labenz C
    JHEP Rep; 2023 Apr; 5(4):100671. PubMed ID: 36866390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural history of covert hepatic encephalopathy: An observational study of 366 cirrhotic patients.
    Wang AJ; Peng AP; Li BM; Gan N; Pei L; Zheng XL; Hong JB; Xiao HY; Zhong JW; Zhu X
    World J Gastroenterol; 2017 Sep; 23(34):6321-6329. PubMed ID: 28974899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Higher scores in the Clinical Frailty Scale are associated with covert and overt hepatic encephalopathy in patients with cirrhosis.
    Schleicher EM; Kaps L; Schattenberg JM; Galle PR; Wörns MA; Gairing SJ; Labenz C
    Dig Liver Dis; 2024 Jun; 56(6):1046-1053. PubMed ID: 38105147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minimal hepatic encephalopathy is associated with a higher risk of overt hepatic encephalopathy and poorer survival.
    Gairing SJ; Mangini C; Zarantonello L; Gioia S; Nielsen EJ; Danneberg S; Lok AS; Sultanik P; Galle PR; Labenz J; Thabut D; Marquardt JU; Bloom PP; Lauridsen MM; Montagnese S; Nardelli S; Labenz C
    J Intern Med; 2024 Mar; 295(3):331-345. PubMed ID: 37983845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and Validation of a Prognostic Score to Predict Covert Hepatic Encephalopathy in Patients With Cirrhosis.
    Labenz C; Toenges G; Huber Y; Nagel M; Marquardt JU; Schattenberg JM; Galle PR; Labenz J; Wörns MA
    Am J Gastroenterol; 2019 May; 114(5):764-770. PubMed ID: 30848730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Controlling nutritional status score as a new indicator of overt hepatic encephalopathy in cirrhotic patients following transjugular intrahepatic portosystemic shunt.
    Li J; Feng D; Pang N; Zhao C; Gao L; Liu S; Li L
    Clin Nutr; 2022 Feb; 41(2):560-566. PubMed ID: 35032860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome Prediction of Covert Hepatic Encephalopathy in Liver Cirrhosis: Comparison of Four Testing Strategies.
    Labenz C; Toenges G; Schattenberg JM; Nagel M; Huber Y; Marquardt JU; Labenz J; Galle PR; Wörns MA
    Clin Transl Gastroenterol; 2020 Jun; 11(6):e00172. PubMed ID: 32568474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnosis of covert hepatic encephalopathy: a multi-center study testing the utility of single versus combined testing.
    Duarte-Rojo A; Allampati S; Thacker LR; Flud CR; Patidar KR; White MB; Klair JS; Heuman DM; Wade JB; Gavis EA; Bajaj JS
    Metab Brain Dis; 2019 Feb; 34(1):289-295. PubMed ID: 30506333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of rifaximin against covert hepatic encephalopathy and hyperammonemia in Japanese patients.
    Nakai M; Suda G; Ogawa K; Yoshida S; Hosoda S; Kubo A; Tokuchi Y; Kitagataya T; Yamada R; Shigesawa T; Ohara M; Sho T; Morikawa K; Sakamoto N
    PLoS One; 2022; 17(7):e0270786. PubMed ID: 35776720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.